SG Americas Securities LLC Has $3.11 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

SG Americas Securities LLC raised its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 210.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,085 shares of the biotechnology company's stock after acquiring an additional 6,841 shares during the period. SG Americas Securities LLC's holdings in United Therapeutics were worth $3,109,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of UTHR. Dunhill Financial LLC boosted its holdings in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares in the last quarter. State of Wyoming bought a new position in shares of United Therapeutics during the 4th quarter worth $62,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics during the 4th quarter worth $67,000. Curat Global LLC bought a new position in shares of United Therapeutics during the 1st quarter worth $63,000. Finally, Natixis purchased a new stake in United Therapeutics during the 4th quarter worth about $85,000. Institutional investors own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Bank of America reduced their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday. Cantor Fitzgerald initiated coverage on United Therapeutics in a research note on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price for the company. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Morgan Stanley boosted their price target on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. Finally, Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $393.08.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $283.78, for a total value of $3,121,580.00. Following the sale, the executive vice president now directly owns 36,781 shares of the company's stock, valued at approximately $10,437,712.18. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer now directly owns 8,118 shares in the company, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,500 shares of company stock valued at $20,828,390 over the last three months. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $2.79 on Friday, reaching $283.35. 564,424 shares of the company traded hands, compared to its average volume of 452,608. United Therapeutics Co. has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The company's 50 day moving average is $300.50 and its 200-day moving average is $330.86. The stock has a market capitalization of $12.78 billion, a PE ratio of 12.44, a P/E/G ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the previous year, the company posted $6.17 earnings per share. United Therapeutics's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.